The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer

被引：8

作者：

Adappa, Nithin D. ^{[1
]}

Sung, Chi-Kwang ^{[1
]}

Choi, Bryan ^{[1
]}

Huang, Tian-Gui ^{[2
]}

Genden, Eric M. ^{[1
]}

Shin, Edward J. ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Dept Otolaryngol Head & Neck Surg, New York, NY USA

[2] Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY USA

来源：

OTOLARYNGOLOGY-HEAD AND NECK SURGERY | 2008年 / 139卷 / 03期

关键词：

D O I：

10.1016/j.otohns.2008.05.001

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

OBJECTIVE: To assess immune-based gene therapy in a murine floor of mouth (FOM) squamous cell carcinoma (SCC) model. STUDY DESIGN: In vitro and in vivo testing of immune therapy for SCC. METHODS: Multiple SCC lines were infected by using advRSV-interleukin-12 (IL-12) and advCMV-imerleukin-12/granulocyte macrophage colony-stimulating factor (IL-12/GM-CSF) and monitored for production of IL-12 and GM-CSF. Intratumoral injections of viral vectors were administered with systemic Ig-4-1BB ligand in an orthotopic murine FOM SCC model and followed for tumor size and survival. RESULTS: In vitro. all cell lines produced substantial levels of IL-12 and GM-CSF. In vivo, tumors treated with advCMV-IL-12/GM-CSF and Ig-4-1BBL showed a striking reduction in tumor volume (vs control P < 0.0001) and improved median survival (38 days vs 19 days for control, P < 0.0001). CONCLUSION: Combination immune-based therapies effectively improve Survival in mice bearing FOM SCC over single-modality therapy. (c) 2008 American Academy of Otolarynology-Head and Neck Surgery Foundation. All rights reserved.

引用

页码：442 / 448

页数：7

共 21 条

[1]

Califano J, 1996, CANCER RES, V56, P2488

[2]

CHEN L, REJECTION M IN PRESS

[3]

HANADA K, 1996, J LEUKOCYTE BIOL, P18190

[4] A PHASE-III RANDOMIZED STUDY COMPARING CISPLATIN AND FLUOROURACIL AS SINGLE AGENTS AND IN COMBINATION FOR ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].

JACOBS, C ;

LYMAN, G ;

VELEZGARCIA, E ;

SRIDHAR, KS ;

KNIGHT, W ;

HOCHSTER, H ;

GOODNOUGH, LT ;

MORTIMER, JE ;

EINHORN, LH ;

SCHACTER, L ;

CHERNG, N ;

DALTON, T ;

BURROUGHS, J ;

ROZENCWEIG, M .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :257-263

[5] On guard - activating NK cell receptors [J].

Lanier, LL .

NATURE IMMUNOLOGY, 2001, 2 (01) :23-27

[6] Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis [J].

Moretta, A ;

Bottino, C ;

Vitale, M ;

Pende, D ;

Cantoni, C ;

Mingari, MC ;

Biassoni, R ;

Moretta, L .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :197-223

[7] Limitations of adenovirus-mediated interleukin-2 gene therapy for oral cancer [J].

O'Malley, BW ;

Li, DQ ;

Buckner, A ;

Duan, L ;

Woo, SLC ;

Pardoll, DM .

LARYNGOSCOPE, 1999, 109 (03) :389-395

[8]

OMalley BW, 1996, CANCER RES, V56, P1737

[9]

OMALLEY BW, 1995, CANCER RES, V55, P1080

[10] The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer [J].

OMalley, BW ;

Sewell, DA ;

Li, DQ ;

Kosai, KI ;

Chen, SH ;

Woo, SLC ;

Duan, L .

MOLECULAR ENDOCRINOLOGY, 1997, 11 (06) :667-673

← 1 2 3 →